These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2146724)

  • 1. LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade.
    Jacobi GH
    Recent Results Cancer Res; 1990; 118():174-85. PubMed ID: 2146724
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA; Calle Fernández JR
    Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
    Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J
    Prostate; 1986; 9(4):327-42. PubMed ID: 2947053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic carcinoma of the prostate in both testes of patients treated with LH-RH analogues.
    Hadjissotiriou GG; Papadopoulos S; Rebelakos A
    Br J Urol; 1992 Jun; 69(6):657-9. PubMed ID: 1386273
    [No Abstract]   [Full Text] [Related]  

  • 6. [Contribution to studies on the treatment of cancer of the prostate with D-Trp6-LH-RH].
    Marcellino LR; Campanella A; Bandini M
    Biomed Pharmacother; 1987; 41(9-10):468-72. PubMed ID: 2968123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK; Jacobi GH
    Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone analogs and prostatic cancer.
    Swanson LJ; Seely JH; Garnick MB
    Crit Rev Oncol Hematol; 1988; 8(1):1-26. PubMed ID: 2964939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical or surgical orchidectomy.
    Parmar H; Edwards LE; Phillips RH; Charlton C; Lightman SI
    BMJ; 1991 May; 302(6787):1272. PubMed ID: 1828382
    [No Abstract]   [Full Text] [Related]  

  • 15. How would you like to have an orchidectomy for advanced prostatic cancer?
    Parmar H; Phillips RH; Lightman SL; Edwards L
    Am J Clin Oncol; 1988; 11 Suppl 2():S160-8. PubMed ID: 2977271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1986; 9(2):207-15. PubMed ID: 2944084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.
    Waxman J; Man A; Hendry WF; Whitfield HN; Besser GM; Tiptaft RC; Paris AM; Oliver RT
    Br Med J (Clin Res Ed); 1985 Nov; 291(6506):1387-8. PubMed ID: 2933122
    [No Abstract]   [Full Text] [Related]  

  • 18. [Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation].
    Seppelt U; Bertermann H; Saerbeck C
    Urologe A; 1986 Sep; 25(5):298-301. PubMed ID: 2947371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1985; 7(1):21-30. PubMed ID: 2934692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.